foscarnet / Generic mfg. - LARVOL DELTA

TRIAL IN PROGRESS: A PHASE 2, SINGLE-ARM, MULTICENTER STUDY OF MARIBAVIR FOR CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH LYMPHOID MALIGNANCIES UNDERGOING BISPECIFIC ANTIBODIES (MALMBA) (EBMT 2026) - P2 | "Unlike conventional CMV agents such as ganciclovir, cidofovir, and foscarnet—often restricted by myelosuppression or renal toxicity—maribavir provides robust antiviral activity without hematologic toxicity, supporting its use in immunocompromised populations. No data are available at this stage as the trial is ongoing."

Bispecific • Clinical • P2 data • B Cell Lymphoma • Cytomegalovirus Infection • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • CD8 • IFNG

LETERMOVIR USE IN PEDIATRIC HSCT PATIENTS UNDER 12 YEARS OLD: UPDATED DATA FROM A RETROSPECTIVE MULTICENTER STUDY OF THE PDWP AND IEWP OF THE EBMT (EBMT 2026) - "Conditioning regimens included treosulfan-based (44.5%), TBI-based (32.2%), busulfan-based (15.1%), and other (8.2%). In-vivo T-cell depletion (TCD) was used in 34.2% of patients (ATG 27.4%, Campath 6.8%), and ex-vivo TCD in 11.6%.Table 1: Patient and transplant characteristics With a median follow-up of 1 year (95% CI: 0.9–1.1), the 1-year cumulative incidence of CMV reactivation was 23.8% (95% CI: 16–30) overall, 21.4% (95% CI: 13.6–29.2) during primary prophylaxis, and 32.6% (95% CI: 13.1–45) during secondary prophylaxis (Figure 1)...Among patients with CMV reactivation, one death was attributed to relapsed disease.Letermovir was well tolerated with only two patients experiencing mild gastrointestinal toxicity, and no additional significant adverse events reported.CMV reactivations were managed using standard antiviral strategies, including valganciclovir (n=10), ganciclovir (n=8), foscarnet (n=7), and cidofovir (n=1) or continued letermovir alone (n=8)... In this..."

Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hepatology • Immunology • Infectious Disease • Pediatrics

INTRAVENOUS BRINCIDOFOVIR EFFECTIVELY REDUCES CMV DNAEMIA IN ANTIVIRAL EXPERIENCED IMMUNOCOMPROMISED PATIENTS: RESULTS OF A PHASE 2A CLINICAL TRIAL (EBMT 2026) - P2 | "Brincidofovir (BCV) is a lipid conjugate of cidofovir that overcomes cidofovir's dose-limiting nephrotoxicity while enhancing antiviral activity against CMV and other double-stranded DNA viruses...Most patients (7/9 per Cohort) had failed ≥1 prior CMV antiviral (n=12 GCV or valGCV, 4 foscarnet, 4 letermovir, and 2 maribavir)... IV BCV was effective in reducing CMV DNAemia and was reasonably well tolerated in this population of pre-treated immunocompromised patients with CMV viremia. IV BCV is a potential treatment option for these patients with limited treatment options. These data support further study of IV BCV for treatment of CMV infections in immunocompromised patients."

Clinical • P2a data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease

Dynamic Mixed Populations of Resistant CMV in a Lung Transplant Recipient (ISHLT 2026) - "Despite these changes he required IV ganciclovir for rising viral loads, and after initial testing showed resistance only to cidofovir, the patient was transitioned back to valganciclovir...The patient once again developed viremia, and testing now showed resistance to maribavir, ganciclovir, and cidofovir for which foscarnet was restarted...Viral loads improved, and the patient was eventually transitioned to a letermovir/valganciclovir combination therapy, followed by maribavir/letermovir therapy after testing showed his maribavir resistance had resolved. Subsequent surveillance has shown CMV viral levels managed on dual therapy.Summary Prior literature has shown that antiviral therapy can select for resistant strains if mixed populations are present, leading to changes in genotypic susceptibility testing results over time. We present a case of highly resistance mixed genotype CMV populations with changing resistance profiles, that was successfully treated with salvage..."

Clinical • Fibrosis • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Transplantation

ACICLOVIR-RESISTANT HERPES SIMPLEX VIRUS IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: A CASE SERIES (EBMT 2026) - "All patients were treated with second-line antivirals (foscarnet and/or cidofovir), and three patients were treated with third-line antivirals (pritelivir). Aciclovir-resistant HSV infection in pediatric HSCT recipients is associated with high morbidity and mortality, limited therapeutic options, and significant treatment-related toxicity. Early recognition, resistance testing, timely initiation of second-line therapy and weaning of immunosuppression are critical for disease control. Emerging therapies, such as helicase-primase inhibitors and adoptive T-cell therapy, hold promise but remain limited by access and pediatric data."

Clinical • Bone Marrow Transplantation • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Herpes Simplex • Immunology • Infectious Disease • Inflammation • Keratitis • Leukemia • Myelodysplastic Syndrome • Ocular Inflammation • Ophthalmology • Pediatrics • Pneumonia • Primary Immunodeficiency • Respiratory Diseases • Sickle Cell Disease • Transplantation • Transplantation Associated Thrombotic Microangiopathy

PRITELIVIR DEMONSTRATED SUPERIOR EFFICACY COMPARED TO INVESTIGATOR'S CHOICE TREATMENT FOR REFRACTORY HERPES SIMPLEX VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS: PRIOH-1, PHASE 3 SAFETY AND EFFICACY (EBMT 2026) - P3 | " In this randomized (1:1), controlled, open label trial, 101 IC patients (≥16 years) with R±R HSV mucocutaneous infection received oral pritelivir (100 mg daily; 400 mg loading dose) or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod) for up to 28 days, extendable to 42 days. Eligibility criteria included hematopoietic cell transplant, solid organ transplant, HIV, malignancy, or chronic use of immunosuppressive treatment with refractory/clinical failure (defined as no clinical improvement of lesions after ≥7 days of standard of care nucleoside analogue therapy or confirmed acyclovir resistance)... Pritelivir met the Phase 3 primary endpoint, demonstrating statistically superior efficacy compared with ICT, with a favorable safety and tolerability profile. These findings support pritelivir as a promising oral agent to address the unmet needs of refractory HSV infections in IC patients.Table 1 Incidence of TEAEs (≥ 10%): Pritelivir vs...."

Clinical • P3 data • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Primary Immunodeficiency • Solid Organ Transplantation

REAL-WORLD USE, EFFECTIVENESS AND SAFETY OF MARIBAVIR IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CMV OR INTOLERANCE TO ANTI-CMV AGENTS: INTERIM ARISE RESULTS (EBMT 2026) - "Interim results of this European retrospective study support the real-world effectiveness and safety of maribavir in adult HCT recipients with refractory/resistant CMV or intolerance to anti-CMV agents. CMV clearance rates at maribavir discontinuation appeared to be higher than previously observed in the HCT population within the phase 3 SOLSTICE trial. The lower incidence of myelosuppression and nephrotoxicity after versus before maribavir initiation is in line with the lower hematologic and renal toxicity of maribavir compared with ganciclovir/valganciclovir and foscarnet in the overall SOLSTICE transplant population."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation

CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (EBMT 2026) - "Regarding GVHD prophylaxis, anti-thymocyte globulin (ATG) was used in 83.8% (n=62) of patients, and post-transplant cyclophosphamide (PTCy) was used in 17.6% (n=13). For pre-transplant antiviral prophylaxis, ganciclovir was administered to 89.2% (n=66) of patients and foscarnet to 21.6% (n=16)... In elderly haplo-HCT recipients, EBV reactivation correlates with inferior survival, whereas early CMV reactivation predicts disease relapse without compromising survival. Letermovir prophylaxis effectively mitigates CMV risk but is independently associated with increased EBV reactivation, presenting a clinical trade-off. These findings highlight the distinct prognostic implications of viral kinetics and underscore the necessity for balanced prophylactic strategies and vigilant monitoring in this vulnerable population."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

MARIBAVIR FOR CYTOMEGALOVIRUS INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL-WORLD, MULTICENTER, COMPARATIVE COHORT STUDY (EBMT 2026) - "All patients tolerated maribavir treatment throughout the study period.Nineteen patients received first-line maribavir for post-HSCT CMV infection, while 20 control patients received other first-line regimens (12 predominantly foscarnet; 8 received combination therapy including ganciclovir or letermovir). In real-world, maribavir demonstrated rapid, effective, and safe clearance of CMV viremia in HSCT recipients. The retrospective cohort study demonstrates comparable CMV clearance rates between first-line maribavir and conventional antiviral regimens in HSCT recipients."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation

THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH ATG/PTCY-BASED GVHD PROPHYLAXIS AS PROMISING APPROACH FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER, OPEN-LABEL, PROSPECTIVE STUDY (EBMT 2026) - "GVHD prophylaxis included ATG (6 mg/kg) plus low-dose PTCy (50 mg/kg), combined with cyclosporine, mycophenolate mofetil, and a short course of methotrexate...Letermovir was used for CMV prophylaxis; CMV reactivation occurred in 7 patients and EBV reactivation in 16, all resolving with ganciclovir, foscarnet, or rituximab... These data suggest that the TBF+ATG/PTCy regimen is feasible for haplo-HSCT in ALL, with manageable transplant-related toxicity. We will further evaluate the regimen by expanding the patient cohort and extending follow-up, which are essential for efficacy and safety analysis."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Mucositis • T Acute Lymphoblastic Leukemia • Transplantation

PROGNOSTIC IMPLICATIONS OF CMV INFECTION/DISEASE AND HHV-6 ENCEPHALITIS IN CORD BLOOD TRANSPLANT RECIPIENTS RECEIVING FOSCARNET (EBMT 2026) - "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis.Primary endpoints were the cumulative incidence of CMV infection and its impact on relapse, non-relapse mortality (NRM), and overall survival (OS)... In CBT with prophylactic FOS, CMV infection was associated with higher NRM, with CMV disease showing a more pronounced impact and adversely affecting OS. Although prophylactic FOS did not sufficiently prevent HHV-6 encephalitis, its occurrence did not affect outcomes."

Clinical • Acute Graft versus Host Disease • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases • Transplantation

CMV INFECTION AFTER ALLOGENEIC HSCT IN SERONEGATIVE RECIPIENTS TRANSPLANTED FROM A SEROPOSITIVE DONOR: A MONOCENTRIC RETROSPECTIVE STUDY (EBMT 2026) - "Since 2017, letermovir (LMV) prophylaxis is recommended after alloHSCT in R+ to decrease the incidence of clinically significant CMV infection (CS-CMVi)...First line pre-emptive treatment was given for a median of 23 days (min: 15, max: 68) and was ganciclovir in 23/24 patients (96%). Eight patients (33.3%) needed second-line foscarnet treatment due to cytopenia (n= 7) or virological failure (n= 1)... In our cohort, the incidence of positive CMV PCR in D+/R- alloHSCT patients was lower than historically reported. LMV significantly reduced the incidence of CMV PCR positivity, and was associated with a trend towards a significant reduction in the incidence of CS-CMVi, maybe due to the small size of the cohort. TBI was the only factor significantly associated with a CMV PCR positivity."

Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation

LATE CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HSCT PERSISTS IN THE ERA OF LETERMOVIR PROPHYLAXIS – A SINGLE-CENTRE REAL WORLD STUDY (EBMT 2026) - "413/480 (86%) received reduced intensity conditioning regimens, and 397/480 were T-cell deplete (Campath 226/480; 47.1%, ATG 93/480; 19.4%, PTCy 79/480; 16.5%)...20/27 (74.1%) of the post-letermovir reactivators required treatment with an additional anti-viral agent (p=0.52); 3 required admission for treatment with foscarnet (2 having been pre-treated with valganciclovir)... CMV reactivation remains a frequent issue post-allo-HSCT. Letermovir defers the median onset of csCMV to post-D100, but does not reduce the need for further anti-viral treatment."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Pneumonia • Retinal Disorders

CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR (EBMT 2026) - "The collected variables included: age, donor/recipient CMV serology, prophylaxis with letermovir, myeloablative or reduced-intensity conditioning, administration of serotherapy and donor type (HLA- identical sibling [MSD], haploidentical with post-transplant cyclophosphamide, other related donors [MMFD] and matched unrelated donor [MUD]. CMV reactivation is a common complication following HSCT. Letermovir could be effective for prophylaxis in seropositive paediatric patients without significant toxicity. In our series, patients who received serotherapy reactivated CMV more frequently."

Clinical • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Gastrointestinal Disorder • Pediatrics • Transplantation

FOSCARNET SODIUM ENEMA FOR REFRACTORY CMV GASTROENTERITIS AFTER HAPLOIDENTICAL HSCT: A CASE SERIES (EBMT 2026) - "Foscarnet sodium enema represents a promising, non-invasive adjunctive therapy for refractory CMV gastroenteritis after allo-HSCT. It can effectively reduce local viral burden and accelerate symptom resolution when systemic drug penetration is insufficient."

Clinical • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder

FOSCARNET SODIUM ENEMA FOR REFRACTORY CMV GASTROENTERITIS AFTER HAPLOIDENTICAL HSCT: A CASE SERIES (EBMT 2026) - "Foscarnet sodium enema represents a promising, non-invasive adjunctive therapy for refractory CMV gastroenteritis after allo-HSCT. It can effectively reduce local viral burden and accelerate symptom resolution when systemic drug penetration is insufficient."

Clinical • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder

FIRST-IN-WORLD EXPERIENCE OF IMMUNOMODULATION TO PROMOTE RECIPIENT TOLERANCE TO GENE MODIFIED AUTOLOGOUS STEM CELL TRANSPLANT FOR MPS II (EBMT 2026) - P1/2 | " Three patients to date have undergone CD34+ cell collection via leukapheresis using G-CSF and plerixafor...For two patients treated following protocol amendment, gene-modified HSCs were transplanted after busulfan-based conditioning with the addition of three doses of alemtuzumab at 0.1mg/kg on day -7 to -5 during conditioning and ongoing sirolimus from day -1 with a target therapeutic range of 5 – 10 micromol/L...The patient did experience transient cytomegaloviraemia, detectable via PCR from day +6, following which they received foscarnet and ganciclovir and successfully cleared viraemia by day +24... The first patient shows early and sustained biochemical correction of nMPSII, and the second patient has undergone the conditioning regimen without concern, confirming the tolerability of our immunomodulation protocol alongside HSCGT. Further follow-up is required to correlate biochemical correction with developmental and cognitive outcomes. Treatment of a further..."

Immunomodulating • CNS Disorders • Gene Therapies • Hunter Syndrome • Immunology • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • Transplant Rejection • Transplantation • CD34 • ITGAM

PERSISTENT HYPONATREMIA AS A DISTINCTIVE FEATURE OF HHV-6B ENCEPHALITIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A CASE SERIES (EBMT 2026) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia during engraftment after HSCT or CRS post-CAR-T therapy could indicate HHV-6B encephalitis in children, highlighting the need for CNS evaluation for diagnosis."

Clinical • IO biomarker • Bone Marrow Transplantation • Cardiovascular • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Inflammation • Juvenile Myelomonocytic Leukemia • Movement Disorders • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • Transplantation • CD7

MANAGEMENT OF SEVERE PULMONARY COMPLICATIONS FOLLOWING HSCT IN A PATIENT WITH Β-THALASSEMIA: A CASE REPORT ON SUCCESSFUL TREATMENT OF CMV PNEUMONIA, DAH, AND BOS (EBMT 2026) - "She underwent a matched unrelated donor (9/10 HLA-matched) allo-HSCT following a myeloablative conditioning regimen (fludarabine, busulfan, cyclophosphamide, ATG). GVHD prophylaxis included tacrolimus, methotrexate, mycophenolate mofetil, and pre-emptive infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs)...The early post-transplant course was complicated by steroid-refractory, grade III acute GVHD (skin and gut), which was successfully managed with a second-line regimen of ruxolitinib, CD25 monoclonal antibody, budesonide, and additional UC-MSCs...Initial anti-CMV therapy (acyclovir/foscarnet) failed, indicating a refractory infection...Treatment with the FAM regimen (fluticasone, azithromycin, montelukast) combined with further cycles of UC-MSCs resulted in significant clinical and radiological improvement by day +220... This complex case illustrates the cascade of severe complications—refractory aGVHD, life-threatening CMV pneumonia with DAH, and..."

Case report • Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

LATE CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HSCT PERSISTS IN THE ERA OF LETERMOVIR PROPHYLAXIS – A SINGLE-CENTRE REAL WORLD STUDY (EBMT 2026) - "413/480 (86%) received reduced intensity conditioning regimens, and 397/480 were T-cell deplete (Campath 226/480; 47.1%, ATG 93/480; 19.4%, PTCy 79/480; 16.5%)...20/27 (74.1%) of the post-letermovir reactivators required treatment with an additional anti-viral agent (p=0.52); 3 required admission for treatment with foscarnet (2 having been pre-treated with valganciclovir)... CMV reactivation remains a frequent issue post-allo-HSCT. Letermovir defers the median onset of csCMV to post-D100, but does not reduce the need for further anti-viral treatment."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Pneumonia • Retinal Disorders

CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (EBMT 2026) - "Regarding GVHD prophylaxis, anti-thymocyte globulin (ATG) was used in 83.8% (n=62) of patients, and post-transplant cyclophosphamide (PTCy) was used in 17.6% (n=13). For pre-transplant antiviral prophylaxis, ganciclovir was administered to 89.2% (n=66) of patients and foscarnet to 21.6% (n=16)... In elderly haplo-HCT recipients, EBV reactivation correlates with inferior survival, whereas early CMV reactivation predicts disease relapse without compromising survival. Letermovir prophylaxis effectively mitigates CMV risk but is independently associated with increased EBV reactivation, presenting a clinical trade-off. These findings highlight the distinct prognostic implications of viral kinetics and underscore the necessity for balanced prophylactic strategies and vigilant monitoring in this vulnerable population."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR (EBMT 2026) - "The collected variables included: age, donor/recipient CMV serology, prophylaxis with letermovir, myeloablative or reduced-intensity conditioning, administration of serotherapy and donor type (HLA- identical sibling [MSD], haploidentical with post-transplant cyclophosphamide, other related donors [MMFD] and matched unrelated donor [MUD]. CMV reactivation is a common complication following HSCT. Letermovir could be effective for prophylaxis in seropositive paediatric patients without significant toxicity. In our series, patients who received serotherapy reactivated CMV more frequently."

Clinical • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Gastrointestinal Disorder • Pediatrics • Transplantation

CMV INFECTION AFTER ALLOGENEIC HSCT IN SERONEGATIVE RECIPIENTS TRANSPLANTED FROM A SEROPOSITIVE DONOR: A MONOCENTRIC RETROSPECTIVE STUDY (EBMT 2026) - "Since 2017, letermovir (LMV) prophylaxis is recommended after alloHSCT in R+ to decrease the incidence of clinically significant CMV infection (CS-CMVi)...First line pre-emptive treatment was given for a median of 23 days (min: 15, max: 68) and was ganciclovir in 23/24 patients (96%). Eight patients (33.3%) needed second-line foscarnet treatment due to cytopenia (n= 7) or virological failure (n= 1)... In our cohort, the incidence of positive CMV PCR in D+/R- alloHSCT patients was lower than historically reported. LMV significantly reduced the incidence of CMV PCR positivity, and was associated with a trend towards a significant reduction in the incidence of CS-CMVi, maybe due to the small size of the cohort. TBI was the only factor significantly associated with a CMV PCR positivity."

Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation

MARIBAVIR FOR CYTOMEGALOVIRUS INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A REAL-WORLD, MULTICENTER, COMPARATIVE COHORT STUDY (EBMT 2026) - "All patients tolerated maribavir treatment throughout the study period.Nineteen patients received first-line maribavir for post-HSCT CMV infection, while 20 control patients received other first-line regimens (12 predominantly foscarnet; 8 received combination therapy including ganciclovir or letermovir). In real-world, maribavir demonstrated rapid, effective, and safe clearance of CMV viremia in HSCT recipients. The retrospective cohort study demonstrates comparable CMV clearance rates between first-line maribavir and conventional antiviral regimens in HSCT recipients."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation

PROGNOSTIC IMPLICATIONS OF CMV INFECTION/DISEASE AND HHV-6 ENCEPHALITIS IN CORD BLOOD TRANSPLANT RECIPIENTS RECEIVING FOSCARNET (EBMT 2026) - "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis.Primary endpoints were the cumulative incidence of CMV infection and its impact on relapse, non-relapse mortality (NRM), and overall survival (OS)... In CBT with prophylactic FOS, CMV infection was associated with higher NRM, with CMV disease showing a more pronounced impact and adversely affecting OS. Although prophylactic FOS did not sufficiently prevent HHV-6 encephalitis, its occurrence did not affect outcomes."

Clinical • Acute Graft versus Host Disease • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases • Transplantation